Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG7388 in Polycythemia Vera and Essential Thrombocythemia
NCT02407080Phase 1Completed
- Sponsor
- John Mascarenhas
- Start
- Apr 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of idasanutlin in polycythemia vera (PV) and essential thrombocythemia (ET) (2 arms), sponsored by John Mascarenhas. Primary endpoints: Dose Limiting Toxicity of RG7388 at 56 days and Dose Limiting Toxicity of Combination RG7388 and Pegasys at 2 years. Started Apr 2015; status: completed.
02
Drugs
idasanutlin
03
Conditions
polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT02407080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02407080.